Impax faces U.S. antitrust trial over generic acne drug's delay

BOSTON (Reuters) – Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *